# A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer

> **NCT01935453** · PHASE1 · COMPLETED · sponsor: **OrienGene Biotechnology Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Melanoma
- Liver Cancer
- Pancreatic Cancer
- Lung Cancer

## Interventions

- **BIOLOGICAL:** Recombinant hGM-CSF Herpes Simplex Virus Injection

## Key facts

- **NCT ID:** NCT01935453
- **Lead sponsor:** OrienGene Biotechnology Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-05
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-09-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01935453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01935453, "A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01935453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*